Birmingham, United Kingdom

Phillip Lr Nicolson

This inventor holds 1 USPTO granted patent. Top assignee: Principia Biopharma Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Phillip Lr Nicolson. Retrieved from https://idiyas.com/inventor/phillip-lr-nicolson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Phillip Lr Nicolson: Patent Activity in Thrombocytopenia Treatment

Introduction

Phillip Lr Nicolson is an inventor associated with Birmingham, Great Britain. His patent work concerns potential treatments for drug-induced thrombocytopenia and vaccine-induced thrombosis and thrombocytopenia syndrome.

Latest Patents

Nicolson is associated with 1 patent: “Methods for Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds.” The patent describes methods for treating or preventing drug-induced thrombocytopenia (DITP) and vaccine-induced thrombosis and thrombocytopenia syndrome (VITT) using certain BTK inhibitors or pharmaceutically acceptable salts of those compounds.

Career Highlights

Nicolson is associated with Principia Biopharma Inc. His listed patent reflects research into therapeutic approaches for immune-related platelet disorders.

Collaborations

His listed coworkers include Christopher W Smith and Steve P Watson. Their names are associated with the patent work described above.

Conclusion

Phillip Lr Nicolson’s recorded invention focuses on BTK inhibitor-based approaches to treating or preventing DITP and VITT, representing his documented contribution to pharmaceutical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…